LumiraDx (Nasdaq: LMDX), a UK-based next-generation point of care diagnostics company, announced on Friday that the outcome from ongoing testing and monitoring of COVID-19 variants indicate that its SARS-CoV-2 Antigen test detects the Omicron Variant.
The company said that in-house wet testing with live Omicron virus indicated that the test detects the Omicron variant with comparable sensitivity to other variants. In the original United States Food and Drug Administration (FDA) Emergency Use Authorisation (EUA) clinical studies, the test indicated 100% agreement with RT-PCR up to Ct 33.0.
The LumiraDx SARS-CoV-2 Antigen test has not been FDA cleared or approved, but has been authorized by FDA under an EUA for use by authorised laboratories. The product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens.
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML